All Articles

BENEFIT: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib Versus Isatuximab Plus Lenalidomide and Dexamethasone in Transplant-Ineligible NDMM

Evolving Landscapes in Multiple Myeloma

Web Exclusives

Results of the BENEFIT study provide evidence that a weekly bortezomib regimen in isatuximab plus bortezomib, lenalidomide, and dexamethasone can be an effective and feasible option for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM).

CEPHEUS: Daratumumab + Bortezomib/Lenalidomide/Dexamethasone for Transplant-Ineligible or -Deferred NDMM

Evolving Landscapes in Multiple Myeloma

Web Exclusives

The results of CEPHEUS support the use of daratumumab-based quadruplet therapy for transplant-ineligible or -deferred newly diagnosed multiple myeloma (NDMM).

Respect in the Oncology Navigation Setting

By Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN

The Editor’s Take

November 2024 Vol 15, No 11

The term “lay navigator” is derogatory toward the patient navigators who have training in an oncology health–related field and who are recognized by the Centers for Medicare & Medicaid Services as professionals entitled to reimbursement for their specialized services.

Development and Implementation of the Zone Tool for Oncology: A Simple Patient Teaching Tool

By Deanna Schlifke, BSN, RN, OCN; Lin Michelle Tabar, MSN, RN, OCN, CMSRN; Mary Baker, DNP, RN, FNP-C, AOCNP, CHFN, GS-C; Sarah Sumner, PhD, RN, OCN, CCRN, CHPN

Original Research

November 2024 Vol 15, No 11

Researchers share findings from a study on the creation and early use of the Zone Tool for Oncology, a geriatric-friendly, single-page, color-coded symptom self-assessment tool for patients undergoing anticancer treatment.

Clinical Trial Catalyst: Empowering Patients to Talk About Clinical Trials

By Kendra Paabo, BSN, RN; Jennifer West, BSN, RN, CCRC, ONN-CG

Clinical Trial Catalyst, Clinical Trials

November 2024 Vol 15, No 11

In this fourth installment of a 5-part series, the authors provide tools for navigators to effectively guide patients through the clinical trial experience, with a focus on molecular profiling and genetic testing.

Post-CRT Durvalumab: A Game-Changer for SCLC

Lung Cancer

November 2024 Vol 15, No 11

Durvalumab consolidation therapy improved overall and progression-free survival in patients with limited-stage small cell lung cancer that did not progress after standard-of-care concurrent chemoradiotherapy.

International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer

Highlights From IASLC

November 2024 Vol 15, No 11

Explore curated coverage of select research presented at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.

The CATCH: In Support of Symptom Management

The CATCH

November 2024 Vol 15, No 11

The November 2024 CATCH is awarded to Sherry Reji, Oncology Nurse Navigator With MD Anderson Cancer Center.

Reclaiming Intimacy: Exploring the Impact of Cancer on the Sexual Self Sexual Health

Sexuality and Cancer

November 2024 Vol 15, No 11

A cancer diagnosis can have a critical impact on sexual health. It is therefore crucial that sexual health be routinely addressed to mitigate distress, enhance patient care, and improve quality of life.

WCLC 2024 HER2-Mutated NSCLC

Longer-Term Follow-Up of Amivantamab + Lazertinib vs Osimertinib From the MARIPOSA Study

Rapid Reactions

Video Library

In the final video of this Rapid Reactions series, Beth Sandy, MSN, CRNP, FAPO, discusses data that continue to favor first-line amivantamab plus lazertinib over osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer after a median of 31 months of follow-up.

All Articles

Page 15 of 281

Connect with Us

Subscribe Today!

I'd like to receive:

Please enter your mailing address.